Picture loading failed.

Anti-PDCD1;LAG3 therapeutic antibody (Pre-made Tebotelimab biosimilar,Bispecific scFv with Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tebotelimab (MGD013) is a bispecific monoclonal antibody. It is anticipated that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-556-1mg 1mg Inquiry
GMP-Bios-ab-556-10mg 10mg Inquiry
GMP-Bios-ab-556-100mg 100mg Inquiry
GMP-Bios-ab-556-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1;LAG3 therapeutic antibody (Pre-made Tebotelimab biosimilar,Bispecific scFv with Crossover)
INN Name Tebotelimab
TargetPDCD1;LAG3
FormatBispecific scFv with Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesMacroGenics
Conditions Approvedna
Conditions ActiveGastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours
Conditions Discontinuedna
Development Techna